Form 4: Merck Executive Richard R. DeLuca Reports Changes in Beneficial Ownership

Richard R. DeLuca, EVP & President of Merck Animal Health, reports acquisition and disposal of Merck & Co., Inc. common stock.

Summary

• Richard R. DeLuca, an executive at Merck & Co., Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On January 27, 2025, DeLuca acquired 25,438 shares of common stock at a price of $97.94 per share due to the satisfaction of performance criteria for performance share units granted on March 31, 2022.
• These performance shares were paid out at 169 percent of target awards and include dividends accrued over the three-year performance period ending December 31, 2024.
• DeLuca also disposed of shares held in the 401(k) plan.
• Following these transactions, DeLuca directly owns 178,992.711 shares and indirectly owns 1,266.1099 shares through the 401(k) plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the vesting of performance share units at a rate of 169% of the target, indicating strong performance. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• The vesting of performance share units at 169% of target suggests strong performance relative to the set goals.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• The vesting of performance share units reflects positively on the company's performance, which benefits shareholders.

Key Dates